
Despite the development and application of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world, the scientific community is still trying to find some therapies to avoid or ameliorate the fatal evolution of the Coronavirus disease 2019 (COVID-19). However, the evidence needs to be stronger to conclude ivermectin's usefulness in the clinical evolution of patients infected with SARS-CoV-2. Therefore, we evaluate the efficacy and safety of ivermectin in treating Mexican patients with asymptomatic and mild COVID-19 in a three-day administration compared to a placebo. At standard doses, ivermectin is ineffective in preventing progression to a severe state or reducing symptoms in adults with asymptomatic and mild COVID-19.
Like
Save
Share